HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years

Journal of Hepatology

Volumn 56, Issue 6, 2012, Pages 1254-1258

  Fasano, Massimo ^a   Lampertico, Pietro ^b   Marzano, Alfredo ^c   Di Marco, Vito ^d   Anna Niro, Grazia ^e   Brancaccio, Giuseppina ^f   Marengo, Andrea ^c   Scotto, Gaetano ^g   Rossana Brunetto, Maurizia ^h   Battista Gaeta, Giovanni ^f   Rizzetto, Mario ^c   Angarano, Gioacchino ^a   Santantonio, Teresa ^g  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c AOU San Giovanni Battista   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF FOGGIA   (Italy)

^h UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Chronic hepatitis B; Lamivudine; Nucleos(t)ide analogues; Viral resistance

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; AGED; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 84861185904     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.01.022     Document Type: Article

References (20)

1. C.L. Lai, R.N. Chien, N.W. Leung, T.T. Chang, R. Guan, and D.I. Tai A one year trial of lamivudine for chronic hepatitis B N Engl J Med 339 1998 61 68 (Pubitemid 28304879)
2. J.L. Dienstag, E.R. Schiff, T.L. Wright, R.P. Perrillo, H.W.L. Hann, and Z. Goodman For the US Lamivudine Investigator Group. Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256 1263 (Pubitemid 29489740)
3. J.L. Dienstag, R.D. Goldin, E.J. Heathcote, H.W.L. Hann, M. Woessner, and S.L. Stephenson Histological outcome during long-term lamivudine therapy Gastroenterology 24 2003 105 117 (Pubitemid 36055344)
4. M. Rizzetto, N.C. Tassopoulos, R.D. Goldin, R. Esteban, T. Santantonio, and E.J. Heathcote Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B J Hepatol 42 2005 173 179 (Pubitemid 40143462)
5. Y.F. Liaw, J.J.Y. Sung, W.C. Chow, G. Farrell, and C.Z. Lee Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
6. A.S. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, and E.R. Schiff Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1727
7. C.L. Lai, J. Dienstag, E. Schiff, N.W. Leung, M. Atkins, and C. Hunt Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 2003 687 696 (Pubitemid 36337972)
8. V. Di Marco, A. Marzano, P. Lampertico, P. Andreone, T. Santantonio, and P.L. Almasio Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to Lamivudine Hepatology 40 2004 883 891 (Pubitemid 39288121)
9. F. Zoulim, and S. Locarnini Hepatitis B resistance to nucleos(t)ide analogues Gastroenterology 137 2009 1593 1608
10. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
11. A.S.F. Lok, and B.J. McMahon AASLD Practice Guidelines. Chronic hepatitis B: update 2009 Hepatology 50 2009 1 36
12. W. Chotiyaputta, C. Peterson, F.A. Ditah, D. Goodwin, and A.S.F. Lok Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B J Hepatol 54 2011 12 18
13. C. Hongthanakorn, W. Chotiyaputta, K. Oberhelman, R.J. Fontana, J.A. Marrero, and T. Licari Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice Hepatology 53 2011 1854 1863
14. Y. Hashimoto, F. Suzuki, and M. Hirakawa Clinical and virological effects of long-term (over 5 years) Lamivudine therapy J Med Virol 82 2010 684 691
15. M.R. Brunetto, F. Moriconi, and F. Bonino Hepatitis B surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
16. R. Moucari, V. Mackiewicz, and O. Lada Early serum HBsAg drop: a strong predictor of sustained virological response to pegilated interferon alfa-2a in HBeAg-negative patients Hepatology 49 2009 1151 1157
17. E.K. Manesis, E.S. Hadziyannis, O.P. Angelopoulou, and S.J. Hadzyannis Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels Antivir Ther 12 2007 73 82 (Pubitemid 46340428)
18. M. Kobayashi, F. Suzuki, N. Akuta, T. Hosaka, T. Sezaki, and H. Yatsuju Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine J Med Virol 79 2007 1472 1477 (Pubitemid 47328735)
19. O. Borgniet, P. Parvaz, and C. Bouix Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B J Med Virol 81 2009 1336 1342
20. A. Gramenzi, E. Loggi, L. Micco, C. Cursaro, S. Fiorino, and S. Galli Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients J Viral Hepat 18 2011 e468 e474